$6.40▴ 2.73%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$4.32MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+2.1%year over year
Watch
Revenue growth has flattened.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 717% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Gyre Therapeutics, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue growth has flattened.
Key numbers
Valuation
EPS (TTM)$-0.09
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-3.1%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$117.05M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.